NYSE
ADCT

Adc Therapeutics SA

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Adc Therapeutics SA Stock Price

Vitals

Today's Low:
$0.95
Today's High:
$1.02
Open Price:
$1
52W Low:
$2.68
52W High:
$16.04
Prev. Close:
$1.04
Volume:
505879

Company Statistics

Market Cap.:
$225.80 million
Book Value:
1.103
Revenue TTM:
$209.91 million
Operating Margin TTM:
-58.9%
Gross Profit TTM:
$17.43 million
Profit Margin:
-74.22%
Return on Assets TTM:
-13.47%
Return on Equity TTM:
-122.29%

Company Profile

Adc Therapeutics SA had its IPO on 1979-03-16 under the ticker symbol ADCT.

The company operates in the Healthcare sector and Biotechnology industry. Adc Therapeutics SA has a staff strength of 0 employees.

Stock update

Shares of Adc Therapeutics SA opened at $1 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.95 - $1.02, and closed at $0.96.

This is a -8.17% slip from the previous day's closing price.

A total volume of 505,879 shares were traded at the close of the day’s session.

In the last one week, shares of Adc Therapeutics SA have slipped by -21.72%.

Adc Therapeutics SA's Key Ratios

Adc Therapeutics SA has a market cap of $225.80 million, indicating a price to book ratio of 2.5787 and a price to sales ratio of 1.6407.

In the last 12-months Adc Therapeutics SA’s revenue was $209.91 million with a gross profit of $17.43 million and an EBITDA of $-122528336. The EBITDA ratio measures Adc Therapeutics SA's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Adc Therapeutics SA’s operating margin was -58.9% while its return on assets stood at -13.47% with a return of equity of -122.29%.

In Q4, Adc Therapeutics SA’s quarterly earnings growth was a positive 0% while revenue growth was a positive 310.3%.

Adc Therapeutics SA’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.71 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Adc Therapeutics SA’s profitability.

Adc Therapeutics SA stock is trading at a EV to sales ratio of 0.0382 and a EV to EBITDA ratio of -0.0402. Its price to sales ratio in the trailing 12-months stood at 1.6407.

Adc Therapeutics SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$529.17 million
Total Liabilities
$98.96 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Adc Therapeutics SA ended 2024 with $529.17 million in total assets and $0 in total liabilities. Its intangible assets were valued at $529.17 million while shareholder equity stood at $88.73 million.

Adc Therapeutics SA ended 2024 with $0 in deferred long-term liabilities, $98.96 million in other current liabilities, 7312000.00 in common stock, $-1080685000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $326.44 million and cash and short-term investments were $326.44 million. The company’s total short-term debt was $13,571,000 while long-term debt stood at $97.24 million.

Adc Therapeutics SA’s total current assets stands at $446.02 million while long-term investments were $31.15 million and short-term investments were $0. Its net receivables were $72.97 million compared to accounts payable of $12.35 million and inventory worth $18.56 million.

In 2024, Adc Therapeutics SA's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Adc Therapeutics SA paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.96
52-Week High
$16.04
52-Week Low
$2.68
Analyst Target Price
$12.29

Adc Therapeutics SA stock is currently trading at $0.96 per share. It touched a 52-week high of $16.04 and a 52-week low of $16.04. Analysts tracking the stock have a 12-month average target price of $12.29.

Its 50-day moving average was $1.46 and 200-day moving average was $2.64 The short ratio stood at 19.4 indicating a short percent outstanding of 0%.

Around 3266.2% of the company’s stock are held by insiders while 6202.6% are held by institutions.

Frequently Asked Questions About Adc Therapeutics SA

The stock symbol (also called stock or share ticker) of Adc Therapeutics SA is ADCT

The IPO of Adc Therapeutics SA took place on 1979-03-16

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$2.41
0.01
+0.42%
$9.62
0.34
+3.66%
$1510.35
-64.2
-4.08%
$4.27
0.08
+1.91%
$0.84
0.02
+2.44%
View Inc (VIEW)
$11.2
-0.7
-5.88%
$0.38
-0
-0.42%
$4.01
-0.05
-1.23%
$21.28
-0.42
-1.94%
$39.89
-0.03
-0.08%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Address

Biopole, Epalinges, Switzerland, 1066